This study investigates HER2-positive solid tumors. It focuses on patients who have advanced or metastatic tumors and have already tried other treatments.
The study looks at how well the investigational medication works in a real-world setting. It evaluates the response rates and how long the response lasts.
- Who can participate: Adults aged 18 and older with HER2-positive solid tumors may join. Patients must have tried other treatments and have no other options.
- Study details: Participants will receive an investigational medication as per FDA guidelines.
How understandable was the trial content above?
Hard to understand
Easy to understand